Novacyt Picks Up Bargain With Omega's Infectious Disease Unit
Clinical diagnostics firm Novacyt's M&A growth strategy is underway with the company announcing a bargain deal to buy the infectious disease business of Omega Diagnostics.
You may also be interested in...
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.
At the LSX World Congress in London, leaders from Medtronic, Johnson & Johnson and Olympus discussed the evolving medtech mergers and acquisitions landscape, the big opportunity in robotic surgery and the impacts on innovation of the forthcoming EU Medical Device Regulation.
Israeli start-up Serenno Medical is targeting 2020 for US FDA clearance and launch of its Sentinel device for early detection and prevention of acute kidney injury, a condition that affects 19 million patients worldwide every year.